Patrick Enright
Jazz PharmaceuticalsAbout Patrick G. Enright
Patrick G. Enright (age 63) is an independent director at Jazz Pharmaceuticals. He has served on Jazz’s board since 2009 (including predecessor Jazz Pharmaceuticals, Inc.) and continued after the Azur Merger in 2012. Enright is co‑founder and Managing Director of Longitude Capital (since 2006), with prior operating roles at Valentis, Boehringer Mannheim, and Sandoz; he holds a B.S. in Biological Sciences from Stanford and an MBA from Wharton. Jazz’s board has designated him an Audit Committee “financial expert,” reflecting deep financial and life sciences operating expertise .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Longitude Capital | Co‑founder, Managing Director | 2006–present | Life sciences investing; board representation across biotech portfolio |
| Pequot Ventures (now FirstMark Capital) | Managing Director (co‑led life sciences) | 2002–2007 | Led life sciences investing practice |
| Valentis; Boehringer Mannheim (acq. by Roche); Sandoz (now Novartis) | Senior executive roles (life sciences operations) | Not disclosed | Senior ops roles across development/commercial functions |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Vera Therapeutics, Inc. | Director | Current | Biotechnology company |
| BioAge Labs Inc. | Director | Current | Biotechnology company |
| Zenas BioPharma, Inc. | Director | Current | Biotechnology company |
| Several privately held healthcare companies | Director | Current | Board service in private healthcare companies |
Board Governance
- Independence: Board has affirmatively determined all directors other than the CEO are independent; Enright is independent .
- Committees and roles (as of June 1, 2025):
- Audit Committee – Member; designated as an “Audit Committee financial expert” by the board .
- Compensation and Management Development Committee – Member .
- Committee activity context: Audit met 4 times in 2024; Compensation met 5 times in 2024 .
- Board service/tenure: Director since 2009 (includes predecessor board), continuing director and 2025 nominee slate .
- Attendance and engagement: In 2024, the board met 10 times; each director attended at least 75% of board and relevant committee meetings; all 12 directors attended the 2024 AGM. Independent directors held executive sessions at each regular board meeting .
- Other current public boards (company disclosure): Table indicates three other current public boards for Enright (see “Our Board” summary) .
Fixed Compensation (Non‑Employee Director – 2024)
| Component | Amount | Notes |
|---|---|---|
| Annual cash retainer | $75,000 | Standard for all independent directors |
| Audit Committee member fee | $15,000 | Paid quarterly |
| Compensation Committee member fee | $12,500 | Paid quarterly |
| Total cash fees earned (FY2024) | $102,500 | Matches Enright’s 2024 cash fees |
| Meeting fees | None | No separate standard meeting fees; Transaction Committee has per‑meeting fees (not applicable) |
Performance Compensation (Equity)
| Metric | Grant Date | Shares/Units | Grant‑Date Fair Value | Vesting |
|---|---|---|---|---|
| Annual Director RSU | Aug 2, 2024 | 3,731 | $422,573 | Vests in full on first anniversary of AGM (time‑based) |
- Structure: Directors receive an automatic annual RSU grant targeted at $400,000 (share count based on 30‑day average price). Awards are time‑vested; no performance metrics apply to director equity .
- Director compensation cap: Aggregate annual director compensation capped at $750,000; $1,350,000 if joining mid‑cycle .
Other Directorships & Interlocks
| Company | Capacity | Interlock/Conflict Notes |
|---|---|---|
| Vera Therapeutics, Inc.; BioAge Labs Inc.; Zenas BioPharma, Inc. | Director | No related‑party transactions with Jazz disclosed; board independence affirmed; Related Party policy requires Audit Committee review of any transaction >$120k involving directors . |
Expertise & Qualifications
- Financial and audit expertise; designated “Audit Committee financial expert” .
- Extensive biopharma operating experience; M&A/corporate development; public company board experience; industry expertise (biotech/pharma) .
Equity Ownership
| Item | Amount/Status | Notes |
|---|---|---|
| Total beneficial ownership (as of May 12, 2025) | 36,251 shares | “<1%” of outstanding shares |
| Options exercisable within 60 days | 15,305 | Included in beneficial ownership |
| Outstanding director RSUs (12/31/2024) | 3,731 | From 2024 director grant |
| Ownership guidelines | 5× annual cash retainer within 5 years; Enright in compliance as of Apr 1, 2025 (all non‑new directors) | |
| Hedging/pledging | Prohibited by company policy (applies to directors) |
Governance Assessment
- Strengths: Independent director with dual committee service; board‑designated financial expert; strong attendance culture; equity‑heavy director pay aligned via time‑vested RSUs; robust director ownership guidelines (compliance achieved); anti‑hedging/pledging and clawback frameworks in place (companywide) .
- Compensation alignment: 2024 director mix balanced—cash fees of $102,500 and RSUs valued at $422,573; equity vests annually, promoting alignment without short‑term metrics; aggregate comp within policy caps .
- Conflicts/related‑party exposure: No Enright‑related transactions disclosed for 2024; Related Party policy provides Audit Committee oversight. One disclosed related‑party employment involved another director’s family member, not Enright .
- Attendance/engagement signals: Board met 10 times; independent sessions held; all directors ≥75% attendance and AGM participation—supportive of board effectiveness .
RED FLAGS: None disclosed specific to Enright (no related‑party transactions; no pledging; independence affirmed) .
Context signals: Say‑on‑Pay support of ~91% at 2024 AGM (for executive pay) indicates constructive shareholder environment, indirectly supportive of board oversight credibility .
Citations: